Neurological Biomarkers Market Report 2026

The neurological biomarkers market size has grown rapidly in recent years. It will grow from $11.92 billion in 2025 to $13.52 billion in 2026 at a compound annual growth rate (CAGR) of 13.4%. The growth in the historic period can be attributed to rising prevalence of neurological disorders, early development of protein biomarkers, increased use of imaging biomarkers, growing adoption of dna biomarkers, initial integration of biomarkers in clinical trials.

The neurological biomarkers market size is expected to see rapid growth in the next few years. It will grow to $22.82 billion in 2030 at a compound annual growth rate (CAGR) of 14%. The growth in the forecast period can be attributed to expanding use of biomarker-based personalized medicine, rising demand for metabolomics biomarkers, increasing investment in cns drug development, development of next-generation diagnostic platforms, growing application of biomarker-driven disease monitoring. Major trends in the forecast period include growing use of biomarkers in early neurological diagnosis, increasing adoption of proteomic and genomic biomarkers, expansion of imaging biomarkers in cns disorder evaluation, rising demand for biomarkers in drug development pipelines, growing clinical focus on neurodegenerative disease biomarker testing.

The rising prevalence of neurological diseases is expected to drive growth in the neurological biomarker market in the coming years. Neurological disorders impact the brain, spinal cord, and all peripheral nerves. Conditions such as Parkinson’s disease, a neurodegenerative disorder, affect both the neurological system and the body areas controlled by the nerves. Neurological biomarkers play a critical role in enabling early diagnosis of Parkinson’s disease through pathological, biochemical, and genetic testing. For instance, in October 2023, the World Federation of Neurology, a UK-based charity, reported that neurological disorders are now the second-leading cause of death and the primary cause of disability worldwide, affecting over 40 percent of the global population in 2023, with the number of individuals living with brain diseases expected to nearly double by 2050. Consequently, the growing prevalence of neurological disorders is driving demand for neurological biomarkers.

Companies in the neurological biomarkers market are focusing on developing innovative products, such as advanced biomarker blood tests, to enhance diagnostic accuracy and patient evaluation. Biomarker blood tests analyze specific molecules or indicators in the blood that reflect biological conditions, diseases, or physiological processes. For example, in July 2023, Quanterix Corporation, a US-based company specializing in ultra-sensitive digital immunoassay platforms, launched the LucentAD biomarker blood test. This test helps clinicians evaluate patients presenting cognitive symptoms suggestive of early-stage Alzheimer’s disease by quantifying levels of p-Tau 181, a recognized biomarker for Alzheimer’s pathophysiology. While the LucentAD test provides valuable diagnostic information, it is intended to be used alongside other diagnostic tools and not as a stand-alone screening or diagnostic assay.

In April 2024, GE HealthCare, a US-based medical technology company, acquired MIM Software Inc. for an undisclosed amount. Through this acquisition, GE HealthCare aims to enhance precision care by integrating advanced imaging analytics and streamlining clinical workflows, ultimately improving patient outcomes and clinician efficiency. MIM Software Inc., a US-based medical imaging software company, offers advanced imaging solutions that support the identification and analysis of neurological biomarkers, strengthening GE HealthCare’s capabilities in personalized treatment solutions across multiple medical specialties.

Major companies operating in the neurological biomarkers market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Thermos Fisher Scientific Inc., AstraZeneca Plc, Abbott Laboratories, Boehringer Ingelheim International GmbH, Becton Dickinson and Company, Agilent Technologies Inc., Grifols S.A., Eisai Co. Ltd., PerkinElmer Inc., Illumina Inc., Shimadzu Corporation, Waters Corporation, Bio-Rad Laboratories Inc., Mallinckrodt Plc, Qiagen N.V., Luminex Corporation, Siemens Healthineers, Olink Proteomics, Meso Scale Diagnostics, Quanterix Corp., Fujirebio, Cisbio Bioassays SAS, NeuroVision Imaging, Proteome Sciences Plc, Acumen Pharmaceuticals.

North America was the largest region in the neurological biomarkers market in 2025. The regions covered in the neurological biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the neurological biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are affecting the neurological biomarkers market by increasing the cost of imported laboratory reagents, diagnostic analyzers, genomic sequencing tools, and imaging systems required for biomarker evaluation. These tariffs most significantly impact hospital laboratories, clinical diagnostic centers, and research organizations in regions reliant on imported biotechnology products such as Europe and Asia-Pacific. Application areas including Alzheimer’s and Parkinson’s diagnostics face delays in biomarker testing availability and increased operational costs. Still, tariffs are stimulating local manufacturing, encouraging regional biotech innovation, and motivating diversification of biomarker production and supply chains.

The neurological biomarkers market research report is one of a series of new reports that provides neurological biomarkers market statistics, including neurological biomarkers industry global market size, regional shares, competitors with a neurological biomarkers market share, detailed neurological biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the neurological biomarkers industry. This neurological biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A neurological biomarker is a substance that offers objective and measurable information regarding the presence, progression, or characteristics of a neurological disorder or condition. These biomarkers are utilized in clinical practice and play a crucial role in drug development.

The main types of neurological biomarkers include proteomics biomarkers, genomics biomarkers, metabolomics biomarkers, imaging biomarkers, and others. Proteomics biomarkers consist of specific proteins or protein patterns that can be identified and monitored by analyzing proteins in body fluids. They are applied in various conditions, such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, schizophrenia, depression, multiple sclerosis, and spinal muscular atrophy, and are used by hospital laboratories, clinical diagnostic centers, research organizations, and other healthcare and research facilities.

The neurological biomarker market consists of sales of genetic testing kits, electroencephalography (EEG) devices, and biomarker assay kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.